PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PTC THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$61.53+2.29 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
50.1%+163.5 pts over 5 years
Net margin
39.4%+154.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +114.5% | +35.3% | +35.4% | +47.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -82.2% | -81.4% | -104.7% | |
| Return on assets | -44.8% | -22.9% | 29.7% | |
| Current ratio | 5.27 | 4.44 | 2.35 | |
| Debt to equity | 0.82 | 0.64 | – | |
| Net debt to EBITDA | -0.31× | -0.24× | – | |
| Inventory turnover | – | – | – | |
| Capex to revenue | 2.1% | 4.7% | 0.5% | |
| Diluted shares | 34M | 66M | 88M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Ptc Therapeutics generated $1.59B from operations and spent $104.03M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.59B
Used
$104.03M
Capital expenditure$104.03M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin39.4%
×Asset turnover0.75×
×Equity multiplier-3.53×
=Return on equity, FY2025-104.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 39.4% | 0.75× | -3.53× | -104.7% |
| FY2024 | -45.0% | 0.45× | -1.88× | 37.9% |
| FY2023 | -66.8% | 0.52× | -3.09× | 107.5% |
| FY2022 | -80.0% | 0.38× | -10.54× | 323.5% |
| FY2021 | -97.3% | 0.26× | 8.58× | -216.7% |
| FY2020 | -115.1% | 0.20× | 3.56× | -81.4% |
| FY2019 | -82.0% | 0.22× | 2.90× | -53.2% |
| FY2018 | -48.4% | 0.35× | 2.98× | -50.5% |
| FY2017 | -40.6% | 0.59× | 2.39× | -57.2% |
| FY2016 | -171.8% | 0.26× | 1.84× | -82.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$682.64M
- Cash generatingOperating cash flow above zero$711.20M
- Return on assets improvedROA up on the prior year-19.2% → 40.0%
- Earnings backed by cashOperating cash flow above net income$711.20M vs $682.64M
- Less leverageLong-term debt to assets fell16.7% → –
- Better liquidityCurrent ratio rose2.35 → 2.35
- No dilutionShare count did not rise77M → 88M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.43 → 1.02